CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells $366,324.86 in Stock

robot
Abstract generation in progress

CRISPR Therapeutics CEO Samarth Kulkarni recently sold 6,967 shares for $366,324.86, adding to previous sales in January totaling roughly $5.53 million in CRSP stock, reducing his stake by 2.99%. This comes after the company reported a significant earnings and revenue miss, though institutional ownership is high and analyst ratings average a “Hold” with a $64.24 price target. The company specializes in gene-editing therapies for serious diseases, with its lead program CTX001 for sickle cell disease.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)